Literature DB >> 18665959

New visions for basic research and primary prevention of pediatric allergy: an iPAC summary and future trends.

Eckard Hamelmann1, Udo Herz, Pat Holt, Arne Host, Roger P Lauener, Paolo M Matricardi, Ulrich Wahn, Magnus Wickman.   

Abstract

Hydrolyzed formula feeding, delayed introduction of solid food, indoor allergen avoidance, smoke and pollutants avoidance have been applied for several decades as primary preventive measures for allergic diseases. Unfortunately, some of these strategies have had no or modest success. Therefore, resources need to be focused on better understanding of the early allergic events and on interventional studies to investigate new strategies of primary and secondary prevention. Accordingly, this review summarizes the state-of-the-art of genetic, immunological and clinical aspects of primary prevention of allergic diseases. Studies investigating gene-by-gene and gene-by-environment interactions suggest that prevention of allergic diseases must be tailored to the individual genetic susceptibilities ('gene profiling') and environmental exposures. The expanding knowledge on new T cell populations (Th17, TSLP (thymic stromal derived lymphopoietin)-dependent 'inflammatory Th2 cells') is also inspiring new concepts on the origins of allergic diseases. The old concept of 'blocking immunoglobulin G antibodies' has been re-appraised and it is likely to generate novel preventive and therapeutic strategies. The major task for future clinical research is to clearly define the timing of optimal exposure to potential allergens. In addition, the role of microbial products such as certain bacteria, or their components, and of helminths or their larvae at different times in early life, alone or with potential allergens, definitely need to be further investigated. The benefit of efficient allergy prevention, based on focusing resources on novel and promising research lines, will be of prime importance to both affluent countries and other parts of the world where allergy is only currently emerging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18665959     DOI: 10.1111/j.1399-3038.2008.00763.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  3 in total

1.  Evaluation of treatment satisfaction in children with allergic disease treated with an antihistamine: an international, non-interventional, retrospective study.

Authors:  Marta Ferrer; Mário Morais-Almeida; Margarita Guizova; Roman Khanferyan
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 2.  Novel strategies in immunotherapy for allergic diseases.

Authors:  Mohana Rajakulendran; Elizabeth Huiwen Tham; Jian Yi Soh; H P Van Bever
Journal:  Asia Pac Allergy       Date:  2018-04-09

Review 3.  The Molecular Allergen Recognition Profile in China as Basis for Allergen-Specific Immunotherapy.

Authors:  Nishelle D'souza; Milena Weber; Eszter Sarzsinszky; Susanne Vrtala; Mirela Curin; Mirjam Schaar; Victoria Garib; Margarete Focke-Tejkl; Yanqiu Li; Richard Jones; Hao Chen; Rudolf Valenta; Baoqing Sun
Journal:  Front Immunol       Date:  2021-08-27       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.